Cargando…
Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
[Image: see text] Targeted delivery of antigens to antigen-presenting cells (APCs) by utilizing natural anticarbohydrate antibodies is a promising approach for selective uptake and enhanced antigen presentation. Previously, we reported that in the presence of a natural antibody, anti-rhamnose antibo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441943/ https://www.ncbi.nlm.nih.gov/pubmed/30949616 http://dx.doi.org/10.1021/acsomega.9b00029 |
_version_ | 1783407628933660672 |
---|---|
author | Hossain, Md Kamal Vartak, Abhishek Sucheck, Steven J. Wall, Katherine A. |
author_facet | Hossain, Md Kamal Vartak, Abhishek Sucheck, Steven J. Wall, Katherine A. |
author_sort | Hossain, Md Kamal |
collection | PubMed |
description | [Image: see text] Targeted delivery of antigens to antigen-presenting cells (APCs) by utilizing natural anticarbohydrate antibodies is a promising approach for selective uptake and enhanced antigen presentation. Previously, we reported that in the presence of a natural antibody, anti-rhamnose antibody (anti-Rha), the bacterial sugar rhamnose conjugated with liposomal cancer antigen MUC1-Tn enhances antigen presentation by APCs such as dendritic cells by targeting Fc gamma receptors. The idea was to utilize the natural human anti-Rha antibodies present in human serum for targeted delivery of cancer-specific antigens. Recently, we found that the IgG3 antibody isotype was the most prevalent anti-Rha antibody generated in mice immunized with rhamnose-Ficoll (Rha-Ficoll) antigen. In this manuscript, we have conjugated the murine IgG3-Fc with a MUC1-containing cancer vaccine and compared the humoral and cellular immune response to this vaccine with one targeted via the human anti-Rha antibody and to the MUC1 vaccine alone. This Fc approach enhanced antibody production and T-cell proliferation almost to the same level as using the anti-Rha antibody. These results suggest that targeting Fc directly to dendritic cells can be an alternative approach to human anti-Rha for generating effective antigen-primed T-cells. |
format | Online Article Text |
id | pubmed-6441943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-64419432019-04-02 Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity Hossain, Md Kamal Vartak, Abhishek Sucheck, Steven J. Wall, Katherine A. ACS Omega [Image: see text] Targeted delivery of antigens to antigen-presenting cells (APCs) by utilizing natural anticarbohydrate antibodies is a promising approach for selective uptake and enhanced antigen presentation. Previously, we reported that in the presence of a natural antibody, anti-rhamnose antibody (anti-Rha), the bacterial sugar rhamnose conjugated with liposomal cancer antigen MUC1-Tn enhances antigen presentation by APCs such as dendritic cells by targeting Fc gamma receptors. The idea was to utilize the natural human anti-Rha antibodies present in human serum for targeted delivery of cancer-specific antigens. Recently, we found that the IgG3 antibody isotype was the most prevalent anti-Rha antibody generated in mice immunized with rhamnose-Ficoll (Rha-Ficoll) antigen. In this manuscript, we have conjugated the murine IgG3-Fc with a MUC1-containing cancer vaccine and compared the humoral and cellular immune response to this vaccine with one targeted via the human anti-Rha antibody and to the MUC1 vaccine alone. This Fc approach enhanced antibody production and T-cell proliferation almost to the same level as using the anti-Rha antibody. These results suggest that targeting Fc directly to dendritic cells can be an alternative approach to human anti-Rha for generating effective antigen-primed T-cells. American Chemical Society 2019-03-13 /pmc/articles/PMC6441943/ /pubmed/30949616 http://dx.doi.org/10.1021/acsomega.9b00029 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Hossain, Md Kamal Vartak, Abhishek Sucheck, Steven J. Wall, Katherine A. Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity |
title | Liposomal Fc Domain Conjugated to a Cancer Vaccine
Enhances Both Humoral and Cellular Immunity |
title_full | Liposomal Fc Domain Conjugated to a Cancer Vaccine
Enhances Both Humoral and Cellular Immunity |
title_fullStr | Liposomal Fc Domain Conjugated to a Cancer Vaccine
Enhances Both Humoral and Cellular Immunity |
title_full_unstemmed | Liposomal Fc Domain Conjugated to a Cancer Vaccine
Enhances Both Humoral and Cellular Immunity |
title_short | Liposomal Fc Domain Conjugated to a Cancer Vaccine
Enhances Both Humoral and Cellular Immunity |
title_sort | liposomal fc domain conjugated to a cancer vaccine
enhances both humoral and cellular immunity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441943/ https://www.ncbi.nlm.nih.gov/pubmed/30949616 http://dx.doi.org/10.1021/acsomega.9b00029 |
work_keys_str_mv | AT hossainmdkamal liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity AT vartakabhishek liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity AT sucheckstevenj liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity AT wallkatherinea liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity |